The trial involves participants with Hidradenitis Suppurativa (HS), a skin condition that must have been diagnosed at least 6 months before screening

Your skin condition will be evaluated to confirm mild to moderate HS (Hurley Stage I or II) with at least 4 affected areas, without draining tunnels

The affected areas must be present in at least 2 different body locations (such as underarms, groin folds, or under breast areas)

You will be randomly assigned to receive either ruxolitinib 1.5% cream or a placebo cream (cream without active medication)

The cream needs to be applied to affected areas twice daily

This phase of the study will last for 16 weeks

During the treatment period, you cannot use:

– Any antibiotics (topical or oral) for HS treatment

– Topical antiseptics, including products containing chlorhexidine, iodine, bleach, or benzoyl peroxide

Regular soap and water are permitted for cleansing

Your condition will be assessed to measure the treatment’s effectiveness

The main goal is to achieve at least 75% reduction in the number of affected areas

Your skin pain levels will be evaluated if you had significant pain at the start of the study

After the initial 16 weeks, the study continues with an extended treatment period

The same restrictions regarding antibiotics and antiseptics continue through weeks 16 to 20

Regular assessments will continue to monitor your progress